US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Kairos Pharma, Ltd

News headline image
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces 1-for-7 Reverse Stock Split
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Ltd. Provides Letter to Stockholders
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
News headline image
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA